US Stock MarketDetailed Quotes

CRSP CRISPR Therapeutics

Watchlist
  • 40.940
  • +0.460+1.14%
Close Dec 24 13:00 ET
  • 40.969
  • +0.029+0.07%
Post 17:01 ET
3.49BMarket Cap-14.67P/E (TTM)

About CRISPR Therapeutics Company

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Company Profile

SymbolCRSP
Company NameCRISPR Therapeutics
Listing DateOct 19, 2016
Issue Price14.00
Founded2013
CEODr. Samarth Kulkarni, PhD
MarketNASDAQ
Employees407
Fiscal Year Ends12-31
AddressBaarerstrasse 14
CityZug
ProvinceZug
CountrySwitzerland
Zip Code6300
Phone41-41-561-32-77

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Samarth Kulkarni, PhD
  • Chairman of the Board and Chief Executive Officer
  • 12.32M
  • Dr. Raju Prasad
  • Chief Financial Officer and Principal Accounting Officer
  • 5.72M
  • Julianne Bruno
  • Chief Operating Officer
  • --
  • John T. Greene
  • Independent Director
  • 555.06K
  • Dr. Ali Behbahani, M.B.A.,M.D.
  • Independent Director
  • 545.06K
  • Dr. Katherine A. High, M.D.
  • Independent Director
  • 532.56K
  • Sandesh Mahatme, L.L.M.
  • Independent Director
  • --
  • Dr. Simeon J. George, M.B.A.,M.D.
  • Independent Director
  • 542.56K
  • Dr. Douglas A. Treco, PhD
  • Lead Independent Director
  • 552.56K
  • Dr. H. Edward Fleming, M.D.
  • Independent Director
  • 536.24K
  • Dr. Christian Rommel, PhD
  • Independent Director
  • --
  • Dr. Maria Fardis, PhD
  • Independent Director
  • 532.84K
  • James R. Kasinger
  • General Counsel and Secretary
  • 3.51M
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.